FDA Approves Lilly’s Kisunla for the Treatment of Early Symptomatic Alzheimer’s Disease
Kisunla is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says.
August 17, 2026
Breaking News
Can an Office harassment lawyer negotiate a settlement? |
Why is Jack Bodenstein gaining attention? |
Which 100 Series Dash Mats offer the best fit and protection? |
Is oven repair Ottawa worth it for older electric and gas ovens? |
How often should organizations conduct a cloud penetration test? |
